74,600 Shares in Olema Pharmaceuticals, Inc. $OLMA Purchased by Swiss National Bank

Swiss National Bank acquired a new position in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 74,600 shares of the company’s stock, valued at approximately $1,112,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. SG Americas Securities LLC bought a new position in shares of Olema Pharmaceuticals in the 4th quarter valued at about $1,735,000. Jennison Associates LLC acquired a new stake in shares of Olema Pharmaceuticals during the 4th quarter worth approximately $24,100,000. Tema Etfs LLC bought a new stake in shares of Olema Pharmaceuticals during the fourth quarter worth approximately $1,113,000. Nicholas Investment Partners LP bought a new stake in shares of Olema Pharmaceuticals during the fourth quarter worth approximately $1,619,000. Finally, Swedbank AB bought a new stake in shares of Olema Pharmaceuticals during the fourth quarter worth approximately $1,378,000. 91.78% of the stock is owned by institutional investors.

Olema Pharmaceuticals Price Performance

Olema Pharmaceuticals stock opened at $11.45 on Friday. The firm has a market capitalization of $1.00 billion, a P/E ratio of -5.67 and a beta of 2.00. Olema Pharmaceuticals, Inc. has a 1 year low of $4.47 and a 1 year high of $36.26. The business has a 50-day moving average of $11.42 and a 200-day moving average of $16.54. The company has a current ratio of 10.88, a quick ratio of 10.88 and a debt-to-equity ratio of 0.01.

Olema Pharmaceuticals (NASDAQ:OLMA) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.52) EPS for the quarter, meeting analysts’ consensus estimates of ($0.52). On average, equities analysts anticipate that Olema Pharmaceuticals, Inc. will post -2.22 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on OLMA. Guggenheim reduced their price objective on shares of Olema Pharmaceuticals from $38.00 to $35.00 and set a “buy” rating on the stock in a research note on Wednesday, May 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Olema Pharmaceuticals in a research report on Friday, July 17th. Wall Street Zen cut shares of Olema Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, July 25th. Finally, HC Wainwright reissued a “buy” rating on shares of Olema Pharmaceuticals in a research note on Friday, May 22nd. Eleven analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $44.10.

Insider Transactions at Olema Pharmaceuticals

In related news, Director Cyrus Harmon sold 12,500 shares of the business’s stock in a transaction that occurred on Thursday, July 23rd. The shares were sold at an average price of $11.58, for a total transaction of $144,750.00. Following the completion of the transaction, the director owned 715,270 shares in the company, valued at approximately $8,282,826.60. The trade was a 1.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 12.56% of the company’s stock.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.